Get free email notifications about news in VBI Vaccines Inc/BC.

The service is free and you can unsubscribe at any time.

General | People (41) | Filings (338) | Investment rounds (4) | Annual reports (1) | Stock | News

VBI Vaccines Inc/BC SEC Filing Form 8-K Current report 2/2017, submited: 2017-06-19

<< back to list of filings

Form 8-K

An 8-K is a report of unscheduled material events or corporate changes at a company that could be of importance to the shareholders or the Securities and Exchange Commission.

Examples of events reported on an 8-K include acquisition, bankruptcy, resignation of directors, or a change in the fiscal year. Also known as Form 8k.

8-K 1 form8-k.htm






Washington, D.C. 20549






Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of report (Date of earliest event reported): June 19, 2017



(Exact name of registrant as specified in its charter)


British Columbia, Canada   000-37769   N/A

(State or other jurisdiction

of incorporation)


(Commission File



(IRS Employer

Identification No.)



222 Third Street, Suite 2241

Cambridge, Massachusetts

(Address of principal executive offices)   (Zip Code)


(617) 830-3031

(Registrant’s telephone number, including area code)


(Former Name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company [X]


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]






Item 7.01 Regulation FD Disclosure.


On June 19, 2017, VBI Vaccines Inc. (the “Company”) issued a press release. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated by reference in this Item 7.01.


The information disclosed under this Item 7.01, including Exhibit 99.1, hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed “filed” with the U.S. Securities and Exchange Commission nor incorporated by reference into any filing made under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits


Exhibit No.   Description
99.1*   Press Release dated June 19, 2017


* Furnished herewith






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  VBI Vaccines Inc.
Date: June 19, 2017 By: /s/ Jeff Baxter
    Jeff Baxter
    President and Chief Executive Officer






Exhibit No.   Description
99.1*   Press Release dated June 19, 2017


* Furnished herewith




VBI Vaccines Inc/BC Latest filings

Filing dateCompanyFormQuarterYear
2017-08-15VBI Vaccines Inc/BC8-K32017view
2017-07-31VBI Vaccines Inc/BC10-Q32017view
2017-07-27VBI Vaccines Inc/BC8-K32017view
2017-07-11VBI Vaccines Inc/BC8-K32017view
2017-06-28VBI Vaccines Inc/BC8-K22017view
2017-06-26VBI Vaccines Inc/BC8-K22017view
2017-06-23VBI Vaccines Inc/BC422017view
2017-06-19VBI Vaccines Inc/BC8-K22017view
2017-06-16VBI Vaccines Inc/BC422017view
2017-06-16VBI Vaccines Inc/BC422017view